Background Jinshuibao capsules (JSB) have been widely used to treat early diabetic nephropathy (DN), but the specific effects are still inconsistent. A meta-analysis of randomized controlled trials (RCTs) was conducted to evaluate the clinical efficacy of JSB for early DN. Methods Four international databases and four Chinese databases were searched from publication dates to March 1, 2018. The RCTs reporting the results of JSB's specific effects were included, and comparisons were between JSB combined with Angiotensin Receptor Blockers (ARBs) as experimental intervention and ARBs as the control. Included studies' quality was evaluated and the extracted data were analyzed with RevMan 5.3 software. Results Twenty-six RCTs including 2198 early DN participants were adopted in the meta-analysis. The results showed that, compared with the ARBs alone, JSB could remarkably improve the ORR (OR = 3.84; 95% CI: 2.37~6.24; P < 0.00001) and decrease 24 h UTP (MD = −93.32; 95% CI: −128.60 ~−58.04; P < 0.00001), UAER (MD = −24.02; 95% CI: −30.93 ~−17.11; P < 0.00001), BUN (MD = −0.26; 95%: −0.44 ~−0.08; P = 0.005), Scr (MD = −9.07; 95% CI: −14.26 ~−3.88; P = 0.0006), ACR (MD = −17.55; 95% CI: −22.81 ~−12.29; P < 0.00001), Cys-C (MD = −0.60; 95% CI: −0.88 ~−0.32; P < 0.00001), SBP (MD = −3.08; 95% CI: −4.65 ~−1.52; P = 0.0001), DBP (MD = −2.09; 95% CI: −4.00 ~−0.19; P = 0.03), and TG (MD = −0.36; 95% CI: −0.50 ~−0.21; P < 0.00001). However, it showed no significant differences in TC (MD = −0.32; 95% CI: −0.69~0.04; P = 0.08), FBG (MD = 0.04; 95% CI: −0.39~0.47; P = 0.87), HbA1c (MD = −0.26; 95% CI: −0.59~0.06; P = 0.11), and β2-MG (MD = −15.61; 95% CI: −32.95~1.73; P = 0.08). Conclusions This study indicates that JSB is an effective accessory therapeutic medicine for patients with early DN. It contributes to decreasing blood pressure and the content of triglyceride and improving the renal function of early DN patients. However, there is still a need to further verify the auxiliary therapeutic effect of JSB with more strictly designed RCTs with large sample and multiple centers in the future.

Glycyrrhiza uralensis (G. uralensis) is a common medicinal plant that has mainly been used to modulate the pharmaceutical activity of herbal medicines. Although G. uralensis has been shown to affect the expression and activity of the key metabolic enzyme cytochrome P450 (CYP450), the detailed mechanism of this process has yet to be elucidated. The present study aimed to elucidate the effects of bioactive components of G. uralensis on different isoforms of CYP450 and determine the ability of these components to modulate drug properties. In the present study, mRNA levels of CYP1A2, CYP2D6, CYP2E1, and CYP3A4 were investigated by quantitative polymerase chain reaction (qPCR) in HepG2 cells following treatment with the major bioactive compounds of G. uralensis. The activity of CYP450 enzymes was investigated in human liver microsomes using the cocktail probe drug method, and the metabolites of specific probes were detected by UPLC‑MS/MS. The effects of G. uralensis on CYP450 were assessed using bioinformatics network analysis. Several compounds from G. uralensis had various effects on the expression and activity of multiple CYP450 isoforms. The majority of the compounds analysed the inhibited expression of CYP2D6 and CYP3A4. Several CYP isoforms were differentially modulated depending on the specific compound and dose tested. In conclusion, the present study suggested that G. uralensis influenced the expression and activity of CYP450 enzymes. Therefore, caution should be taken when G. uralensis is co‑administered with drugs that are known to be metabolized by CYP450. This study contributed to the knowledge of the mechanisms by which this medicinal plant, commonly known as licorice, modulates drug efficacy.

No abstract

No abstract

Abstract-Objective ：Phospholipids are one of important factors in Hyperlipidemia development. To discover relationship of Hyperlipidemia and phospholipids, we carried out this study. Methods: We carried on the bioinformatics study on the relationship by Cytoscape software with Agilent Literature Search and ClusterONE plugins loaded. To search literatures of the relationship by Agilent Literature Search plugin and the network was generated and laid out in a new window. Loaded the above network into Cytoscape and new networks were generated by cluster analysis. Results: The network generated through Agilent Literature Search plugin includes 72 nodes and 95 edges. 14 clusters were generated by ClusterONE after cluster analysis, in which there are 7 clusters (p-value less than 0.05) were statistically significant, the node size is 3-7. The 7 predominant network pathway which could explain the relationship of Hyperlipidemia and phospholipids. Conclusion :The Cytoscape software with Agilent Literature Search and ClusterONE plugins is very powerful tool for discover potential pathways to explain Pathophysiology mechanism.